Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain excitatory neurons; strongest in hematopoietic stem cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 265 | 0.79 |
| pathways Reactome | 2 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 4107
Sealed predictions
- ALS2 in dopamine neurons, braak+0.63 (p 0.067) → +0.17 (p 0.656)receipt 4116
Swarm cases
receipt 4116: ALS2 in dopamine neurons, braak
- power
- full sample +0.39 (p 0.107, n 18), 95% CI -0.09 to +0.73. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.42 (p 0.084, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.66 (p 0.0031, n 18). not the mix.
- skeptic
- leave-one-out range +0.31 to +0.54, sign flips 0; without severely affected donors +0.39 (p 0.107, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ALS2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts